查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134987

全球視神經脊髓炎治療研發管線分析 - 2026 年（第二季洞察與臨床試驗）

Global Neuromyelitis Optica Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

視神經脊髓炎頻譜疾病（NMOSD）是一種罕見的自體免疫中樞神經系統疾病，主要涉及視神經和脊髓，導致反覆發作。這可導致視力喪失、癱瘓、慢性殘疾和生活品質下降。水通道蛋白4（AQP4）抗體的發現顯著加深了我們對該疾病的理解，並加速了標靶治療的研發。因此，NMOSD的治療模式正迅速從傳統的免疫抑制療法發展到高度標靶化的生物製藥和新一代免疫調節療法。

藥物研發管線分析提供有關新療法、臨床開發項目、管線資產、許可活動、監管里程碑和競爭地位的策略性見解。這些分析有助於製藥公司、生技公司、投資者、醫療機構和研究機構評估視神經脊髓炎譜系疾病 (NMOSD) 市場的未來機會和發展風險。

市場促進因素

標靶免疫療法研發的擴展

  • 推動研發管線成長的主要因素之一是對標靶免疫療法的日益關注，這些療法旨在解決與視神經脊髓炎譜系障礙（NMOSD）相關的特定疾病機制。針對B細胞、補體路徑、白細胞介素訊號路徑和抗體介導的免疫反應的治療方法已展現出令人鼓舞的臨床療效，並持續吸引大量的研究投資。

臨床研發活動活性化

  • 過去十年，隨著製藥和生技公司致力於研發能夠降低復發率並預防不可逆神經損傷的創新療法，視神經脊髓炎譜系疾病（NMOSD）的研發管線顯著擴展。目前，已有多個候選藥物正處於臨床前、I期、II期和III期臨床試驗階段。

加大對罕見疾病領域的投資

  • 罕見神經系統疾病已成為藥物創新領域的重點。孤兒藥激勵政策、加快法規核准流程以及人們對未滿足醫療需求的日益關注，正推動著對視神經脊髓炎譜系疾病（NMOSD）藥物研發計畫的投資不斷增加。這些因素持續促進產品線的拓展和策略合作的建立。

精準醫學的進展

  • 對疾病生物標記、免疫路徑和患者亞型的深入了解正在推動個人化治療方法的發展。精準醫療策略能夠更好地篩選患者、改進臨床試驗設計並實現更有針對性的治療性介入。

市場限制因素

患者數量少

  • 由於視神經脊髓炎譜系障礙（NMOSD）是一種罕見的自體免疫疾病，全球患者數量相對較少。患者數量的有限性使得招募受試者變得困難，並延長了臨床研發週期。

複雜的臨床開發要求

  • 臨床試驗通常需要長期監測，以評估復發預防、殘疾進展、安全性以及治療效果的持久性。這些要求增加了研發成本和營運複雜性。

高昂的開發成本

  • 生物製藥、單株抗體和先進免疫療法的開發需要對研究、生產、監管合規和上市後監測活動進行大量投資。

對技術和管道的洞察

  • 全球 NMOSD 治療藥物研發管線可依研發階段、治療方式、作用機轉、分子類型和給藥途徑分類。
  • 依研發階段分類，產品線涵蓋處於藥物發現階段的候選藥物、臨床前資產、I期、II期和III期臨床試驗、處於監管申報階段的治療藥物以及上市後生命週期管理舉措。行業評估表明，早期創新和後期研發活動之間保持著健康的平衡，從而支持了市場的長期成長。
  • 從治療方式來看，在研藥物包括單株抗體、補體抑制劑、B細胞清除療法、白細胞介素抑制劑、小分子化合物、基因療法、胜肽藥物和新興免疫調節劑。單株抗體目前是研發管線中最先進且最具商業性價值的類別。

從作用機轉來看，在研候選藥物主要針對下列標靶：

  • B細胞清除
  • 補體C5抑制
  • 阻斷白細胞介素-6受體
  • 細胞激素調控
  • 抗體中和作用
  • 誘導免疫耐受
  • 神經保護通路
  • 新型免疫調節標靶
  • 最近的分析表明，B 細胞清除療法在 NMOSD 的臨床開發活動中佔很大比例，其次是補體抑制療法和 IL-6 受體標靶療法。
  • 從分子層面來看，研發管線涵蓋生物製藥、單株抗體、重組蛋白、胜肽藥物、基因療法和小分子療法。生物技術和免疫學的進步正日益豐富治療選擇。

競爭格局

  • NMOSD 的研發管線得到了不斷壯大的製藥公司、生物技術創新者、學術機構和專門從事罕見疾病的開發公司的支持。
  • 業界領導者包括羅氏、安進和Alexion Pharmaceuticals，以及多家致力於研發下一代免疫療法和精準醫療技術的新興生物技術公司。策略聯盟、授權協議、收購和研究夥伴關係在加速藥物發現和開發以及增強產品線方面繼續發揮至關重要的作用。
  • 行業分析表明，超過 10 家公司正在積極開發 12 種以上的 NMOSD 治療候選藥物，這些藥物處於臨床和臨床前階段，反映出市場競爭日益激烈。

未來展望

  • 未來 NMOSD 的研發管線預計將越來越專注於能夠持續預防復發、改善神經系統預後、提高安全性以及提供更個人化治療方法的療法。
  • 新的創新領域包括新一代生物製藥、先進標靶治療、基於生物標記的治療選擇以及旨在解決抗藥性患者群體的新型作用機制。人工智慧、基因組分析、數位健康技術和真實世界數據（RWE）平台有望進一步提高研發效率並加速治療創新。
  • 隨著自體免疫不斷進步，NMOSD 的治療模式將變得越來越多樣化，從而帶來新的治療選擇和改善患者的治療效果。

結論

  • 全球視神經脊髓炎 (NMOSD) 治療研發管線分析市場預計到 2035 年將保持強勁成長，主要驅動力包括不斷擴大的臨床研究、對罕見神經系統疾病投入的增加、靶向免疫療法的進步以及精準醫療策略的普及。儘管受試者招募、研發複雜性和高昂的研發成本等挑戰依然存在，但生物製藥、補體抑制劑、B 細胞療法和新一代免疫調節劑的持續創新有望改變 NMOSD 治療的未來。隨著更多候選藥物走向商業化，該市場將在疾病管理、復發預防和患者長期預後方面取得顯著改善。

本報告的主要特點

  • 深入分析：對 NMOSD 的在研產品、臨床開發活動和新興治療趨勢進行全面評估。
  • 競爭格局：了解產業內的主要開發公司、專案儲備定位和策略趨勢。
  • 市場促進因素與未來趨勢：我們評估了塑造 NMOSD 研發管線的成長機會和技術創新。
  • 實用建議：我們協助制定許可協議決策、投資策略和專案優先排序。
  • 適合廣泛受眾：非常適合製藥公司、生物技術公司、投資者、顧問、研究人員和醫療保健相關人員。

我們報告的用途

  • 產品線基準分析、臨床試驗監測、競爭情報分析、許可評估、合作考慮、投資分析、投資組合規劃、監管策略制定和市場機會識別。

調查範圍

  • 歷史資料涵蓋 2021 年至 2025 年，基準年為 2025 年，預測期間為 2026 年至 2035 年。
  • 依研發階段、治療領域、作用機制和分子類型進行產品線分析。
  • 臨床試驗趨勢、新興療法和監管趨勢
  • 競爭情報、公司概況分析、策略交易分析
  • 未來創新趨勢、商業化機會與市場前景。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：視神經脊髓炎臨床進展的動態

  • 促進因素
  • 抑制因子
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Amgen / Alexion Pharmaceuticals
    • Roche
    • UCB
    • argenx
    • Chugai Pharmaceutical
    • Novartis
    • Johnson & Johnson Innovative Medicine
    • Kyverna Therapeutics
  • 管道分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • AQP4-IgG陽性視神經脊髓炎譜系疾病
    • 血清陰性視神經脊髓炎譜系疾病
    • 其他相關的神經發炎項目
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前尚未招募任何參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 對贊助商和合作組織的分析
  • 近期和即將進行的管道活動
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Amgen/Alexion Pharmaceuticals
  • Roche
  • UCB
  • argenx
  • Chugai Pharmaceutical
  • Novartis
  • Johnson & Johnson Innovative Medicine
  • Kyverna Therapeutics

第7章：圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008871

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune disease of the central nervous system that primarily affects the optic nerves and spinal cord, causing recurrent attacks that can result in vision loss, paralysis, chronic disability, and reduced quality of life. The discovery of aquaporin-4 (AQP4) antibodies has significantly improved disease understanding and facilitated the development of targeted therapies. As a result, the NMOSD therapeutic landscape has evolved rapidly from conventional immunosuppressive treatments toward highly targeted biologics and next-generation immunomodulatory therapies.

Drug pipeline analysis provides strategic insights into emerging therapies, clinical development programs, pipeline assets, licensing activities, regulatory milestones, and competitive positioning. These analyses help pharmaceutical companies, biotechnology firms, investors, healthcare organizations, and research institutions evaluate future opportunities and development risks within the NMOSD market.

Market Drivers

Expanding Development of Targeted Immunotherapies

  • One of the major drivers of pipeline growth is the increasing focus on targeted immunotherapies designed to address specific disease mechanisms involved in NMOSD. Therapeutic approaches targeting B cells, complement pathways, interleukin signaling, and antibody-mediated immune responses have demonstrated promising clinical outcomes and continue to attract substantial research investment.

Growing Clinical Development Activity

  • The NMOSD pipeline has expanded considerably over the past decade as pharmaceutical and biotechnology companies pursue innovative therapies capable of reducing relapse frequency and preventing irreversible neurological damage. Multiple candidates are currently progressing through preclinical, Phase I, Phase II, and Phase III development stages.

Increasing Rare Disease Investment

  • Rare neurological disorders have become an important area of focus for pharmaceutical innovation. Orphan drug incentives, expedited regulatory pathways, and increasing awareness of unmet medical needs have encouraged greater investment in NMOSD drug development programs. These factors continue to stimulate pipeline expansion and strategic collaborations.

Advancements in Precision Medicine

  • Improved understanding of disease biomarkers, immune pathways, and patient subtypes is supporting the development of personalized treatment approaches. Precision medicine strategies are enabling better patient selection, improved clinical trial design, and more targeted therapeutic interventions.

Market Restraints

Limited Patient Population

  • As a rare autoimmune disease, NMOSD affects a relatively small number of patients worldwide. Limited patient availability can complicate recruitment efforts and prolong clinical development timelines.

Complex Clinical Development Requirements

  • Clinical trials often require long-term monitoring to evaluate relapse prevention, disability progression, safety, and treatment durability. These requirements increase development costs and operational complexity.

High Development Costs

  • The development of biologics, monoclonal antibodies, and advanced immunotherapies requires significant investment in research, manufacturing, regulatory compliance, and post-marketing surveillance activities.

Technology and Pipeline Insights

  • The global NMOSD drug pipeline can be segmented by development phase, therapeutic modality, mechanism of action, molecule type, and route of administration.
  • By development phase, the pipeline includes discovery-stage candidates, preclinical assets, Phase I studies, Phase II trials, Phase III programs, registration-stage therapies, and post-marketing lifecycle management initiatives. Industry assessments indicate a healthy balance between early-stage innovation and late-stage development activity, supporting long-term market growth.
  • By therapeutic modality, the pipeline includes monoclonal antibodies, complement inhibitors, B-cell depletion therapies, interleukin inhibitors, small molecules, gene therapies, peptides, and emerging immunomodulatory agents. Monoclonal antibodies currently represent one of the most advanced and commercially important categories within the pipeline.

By mechanism of action, pipeline candidates target:

  • B-cell depletion
  • Complement C5 inhibition
  • Interleukin-6 receptor blockade
  • Cytokine modulation
  • Antibody neutralization
  • Immune tolerance induction
  • Neuroprotection pathways
  • Novel immunomodulatory targets
  • Recent analyses indicate that B-cell depletion programs account for a significant share of NMOSD clinical development activity, followed by complement inhibition and IL-6 receptor-targeted therapies.
  • By molecule type, the pipeline includes biologics, monoclonal antibodies, recombinant proteins, peptides, gene therapies, and small-molecule therapeutics. Advances in biotechnology and immunology continue to diversify the therapeutic landscape.

Competitive Landscape

  • The NMOSD pipeline is supported by a growing network of pharmaceutical companies, biotechnology innovators, academic institutions, and specialized rare disease developers.
  • Leading industry participants include Roche, Amgen, Alexion Pharmaceuticals, and several emerging biotechnology firms pursuing next-generation immunotherapies and precision medicine approaches. Strategic collaborations, licensing agreements, acquisitions, and research partnerships continue to play an important role in accelerating drug development and strengthening pipeline portfolios.
  • Industry assessments indicate that more than 10 companies are actively developing over a dozen investigational NMOSD therapies across clinical and preclinical stages, reflecting the growing competitive intensity within the market.

Future Outlook

  • The future NMOSD pipeline is expected to focus increasingly on therapies capable of delivering durable relapse prevention, improved neurological outcomes, enhanced safety profiles, and more personalized treatment approaches.
  • Emerging areas of innovation include next-generation biologics, advanced immune-targeting therapies, biomarker-driven treatment selection, and novel mechanisms designed to address treatment-resistant patient populations. Artificial intelligence, genomic analytics, digital health technologies, and real-world evidence platforms are expected to further improve development efficiency and accelerate therapeutic innovation.
  • As scientific understanding of autoimmune neurological disorders continues to advance, the NMOSD treatment landscape is likely to become increasingly diversified, offering new therapeutic options and improved patient outcomes.

Conclusion

  • The global Neuromyelitis Optica drug pipeline analysis market is poised for strong growth through 2035, supported by expanding clinical research, increasing investment in rare neurological diseases, advancements in targeted immunotherapies, and growing adoption of precision medicine strategies. While challenges related to patient recruitment, development complexity, and high research costs remain, continued innovation across biologics, complement inhibitors, B-cell therapies, and next-generation immunomodulators is expected to transform the future of NMOSD treatment. As more pipeline candidates advance toward commercialization, the market is likely to witness substantial improvements in disease management, relapse prevention, and long-term patient outcomes.

Key Benefits of this Report

  • Insightful Analysis: Comprehensive evaluation of NMOSD pipeline assets, clinical development activity, and emerging therapeutic trends.
  • Competitive Landscape: Understand key developers, pipeline positioning, and strategic industry developments.
  • Market Drivers and Future Trends: Assess growth opportunities and technological innovations shaping the NMOSD pipeline.
  • Actionable Recommendations: Support licensing decisions, investment strategies, and pipeline prioritization.
  • Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, investors, consultants, researchers, and healthcare stakeholders.

What Businesses Use Our Reports For

  • Pipeline benchmarking, clinical trial monitoring, competitive intelligence, licensing evaluations, partnership assessments, investment analysis, portfolio planning, regulatory strategy development, and market opportunity identification.

Report Coverage

  • Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
  • Pipeline analysis by development phase, therapeutic modality, mechanism of action, and molecule type
  • Clinical trial activity, emerging therapies, and regulatory developments
  • Competitive intelligence, company profiling, and strategic transaction analysis
  • Future innovation trends, commercialization opportunities, and market outlook.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. NEUROMYELITIS OPTICA PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Amgen / Alexion Pharmaceuticals
    • 5.1.2. Roche
    • 5.1.3. UCB
    • 5.1.4. argenx
    • 5.1.5. Chugai Pharmaceutical
    • 5.1.6. Novartis
    • 5.1.7. Johnson & Johnson Innovative Medicine
    • 5.1.8. Kyverna Therapeutics
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. AQP4-IgG Positive NMOSD
    • 5.4.2. Seronegative NMOSD
    • 5.4.3. Other Related Neuroinflammatory Programs
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Amgen / Alexion Pharmaceuticals
  • 6.2. Roche
  • 6.3. UCB
  • 6.4. argenx
  • 6.5. Chugai Pharmaceutical
  • 6.6. Novartis
  • 6.7. Johnson & Johnson Innovative Medicine
  • 6.8. Kyverna Therapeutics

7. LIST OF TABLES

8. LIST OF FIGURES